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Abstract: This paper reviews the current management of onchocerciasis and its future prospects. 
Onchocerciasis is a disease affecting millions of people in Africa, South and Central America, and 
Yemen. It is spread by the blackfly as a vector and caused by the filarial nematode, Onchocerca 
volvulus. A serious attempt was made by the Onchocerciasis Control Program between 1975 
and 2002 to eliminate the vector in eleven of the endemic countries in West Africa, and with 
remarkable success. Formerly, the treatment was with diethyl carbamazine for the microfilaria 
and suramin for the adult worm. These drugs are now known to be toxic and unsuitable for 
mass distribution. In particular, they precipitate optic nerve disease. With the discovery of 
ivermectin, a much safer microfilaricide, and the decision of Merck to distribute the drug free 
of charge for as long as needed, the strategy of control switched to mass drug administration 
through community-directed treatment with ivermectin. So far, millions have received this 
annual or biannual treatment through the African Program for Onchocerciasis Control and the 
Onchocerciasis Elimination Program for the Americas. However, the problem with ivermectin 
is that it is a monotherapy microfilaricide which has limited effect on the adult worm, and thus 
will need to be continued for the life span of the adult worm, which may last up to 15 years. 
There are also early reports of resistance. Serious encephalopathy and death may occur when 
ivermectin is used in subjects heavily infested with loiasis. It seems unlikely that a break in 
transmission will occur with community-directed treatment with ivermectin in Africa because 
of population migrations and the highly efficient vector, but in the Americas some countries 
such as Columbia and the Oaxaca focus in Mexico have reported eradication. Vector control is 
only now applicable in selected situations, and particularly to control the nuisance value of the 
blackfly. Trials are ongoing for alternatives to ivermectin. Candidate drugs include moxidectin, 
a macrofilaricide, doxycycline which targets the Wolbachia endosymbiont, and flubendazole, 
which shows promise with the newer oral cyclodextrin formulation.
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Introduction
The management of onchocerciasis is challenging. Firstly, it has to be carried on at 
both individual and community levels. Secondly, considerations have to be given to 
measures against the vector, ie, the Simulidae species. Thirdly, the ideal treatment of 
the infected individual should be directed at both the adult worm and the microfilaria. 
Finally, treatment has to be directed at skin and ocular disease. Invariably the patient 
with skin disease has eye disease and vice versa, and has to be treated holistically.
Onchocerciasis, also known as river blindness, is an infection caused by the filarial 
nematode, Onchocerca volvulus.1,2 It is transmitted by various species of Simulidae, Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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known as the blackfly.3 It is a problem of major social and 
health significance in various countries of sub-Saharan 
Africa, South and central America, and in some countries 
in the Arabian Peninsula, notably Yemen.1
In 1995, the World Health Organization (WHO) esti-
mated that 122.9 million people worldwide were at risk of 
  infection, of whom approximately 17.7 million were infected 
and about 300,000 were blind.4 More recent estimates have 
been refined by widespread use of rapid epidemiological 
mapping of onchocerciasis methods. In a recent estimate 
published by Amazigo et al, it was suggested that within 
the African Program for Onchocerciasis Control (APOC) 
countries, there are 87 million people at risk, of whom 37 mil-
lion are infected, 300,000 are blind, and a further 500,000 
are visually impaired.5 The Onchocerciasis Control Project 
(OCP) was carried out in Benin, Burkina Faso, Côte d’Ivoire, 
Ghana, Mali, Niger, Sierra Leone, Guinea Republic, Guinea 
Bissau, Senegal, and Togo. The non-OCP countries now 
within the APOC project are African countries which also 
have endemic onchocerciasis but were not included in the 
original OCP area. These include Liberia (which had been 
left out largely due to internal conflict), Cameroon, Chad, the 
Democratic Republic of Congo, Ethiopia, Malawi, Nigeria, 
the Republic of Congo, Sudan, Tanzania, Uganda, Rwanda, 
Burundi, the Central African Republic, Gabon, and Equato-
rial Guinea (see Figures 1 and 2 for a map of the OCP and 
APOC areas). Figure 3 shows the countries covered by the 
Onchocerciasis Elimination Program for the Americas.
Compared with the same statistics put out by WHO in 
1987, the present figures appear to suggest that measures 
taken to control the transmission of onchocerciasis in recent 
times, including the OCP and the ivermectin distribution 
program, have had little impact on the overall number of the 
blind and visually impaired victims of onchocerciasis,6 and it 
is estimated that worldwide, 78 million are at risk, 17 million 
are infected, and over 300,000 are blind. The latest figures are 
probably more precise because rapid epidemiological mapping 
of onchocerciasis has been carried out in several countries.
Dermatologic and ocular 
manifestations
Human involvement includes both dermatologic and ocular 
disease. Skin manifestations have been well described by 
Murdoch et al.7 These include acute and chronic papular 
onchodermatitis, scratch marks, lichenification, and typical 
pigmentary skin changes known as leopard skin. Major   ocular 
Figure 1 Map of Africa showing countries covered by the Onchocerciasis Control Project (OCP) and the African Onchocerciasis Control Programme (APOC).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 2 The Onchocerciasis elimination Program for the Americas (OePA). 
Reproduced with permission from the Carter Foundation. website http://www.cartercenter.org/resources/pdfs/health/river_blindness/OePA-foci.pdf.
Figure 3 Sclerosing Keratitis in an African subject infested with Onchocerca volvulus.
findings in onchocerciasis include corneal changes, such 
as sclerosing keratitis and snowflake opacities, torpid iritis 
characterized by typical pear-shaped deformity of the iris, 
secondary cataracts, choroidoretinopathy, and optic neuritis8 
(see Figures 4 and 5).
The pathogenesis of optic neuritis is not well understood, 
but is believed to be associated with death of microfilaria and 
secondary inflammatory changes.9 The major causes of blind-
ness in these patients are corneal blindness, particularly from 
sclerosing keratitis and chronic torpid iritis in the anterior 
segment, and chorioretinopathy and optic neuropathy in the 
posterior segment.
Most of the ocular changes have been attributed to 
direct infestation with microfilariae, particularly with the 
toxic reaction associated with their death.10 Massive and 
chronic death of the microfilariae is traditionally associated 
with sclerosing keratitis. However, evidence for this is not 
particularly strong. A paper examining the risk factors for 
sclerosing keratitis in the Kaduna State is underway. Death 
of individual microfilaria within the stroma of the cornea 
is associated with snowflake opacities.10 These lesions are 
potentially reversible with appropriate therapy. Some hold 
that sclerosing keratitis is also reversible but, in the author’s 
experience, this is probably optimistic and debatable, and has 
yet to be clearly demonstrated.11 It is possible that, in addition Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The most common vector in the West African subregion 
is Simulium damnosum. However, it must be noted that 
Simulidae are almost universally distributed, even in areas 
where onchocerciasis is not endemic, such as in Scotland.15 
Measures have been taken to control the vectors, particularly 
in the OCP area of West Africa (1975–2002).16 This was a 
multilateral undertaking involving funding from the World 
Bank, the WHO as the executing agency, and the Food and 
Agricultural Organization and United Nations   Development 
Agency taking the lead in development planning. The 
  program aimed to eradicate onchocerciasis as a disease of 
public health concern in the eleven OCP countries west of 
Nigeria. The life cycle of O. volvulus can span 15 years until 
the natural death of the adult worm. Therefore, it is necessary 
to keep up vector control efforts for at least that period of 
time. The OCP, headquartered in Ouagadougou, interrupted 
transmission significantly in the target areas.17 For example, 
data from a Republic of Guinea focus suggest that before 
vector control measures, the mean annual transmission 
potential was about 120 microfilariae per person in 1975. 
By 1985, following annual larviciding, this had dropped to 
less than five per person. Also, the number of infective flies 
and larvae per 1000 parous blackflies dropped from a peak 
of 80 and 50, respectively, to less than 10. These levels are 
considered insufficient to sustain transmission.18 Larviciding 
was carried out using fixed wing planes and helicopters, as 
well as manual means where applicable. The initial chemical 
used was dichloro diphenyl trichloroethane (DDT). However, 
due to the environmental impact of this chemical, particularly 
its prolonged residence time, temephos (Abate®) which has 
a better environmental profile, was introduced and has been 
in use since.19
The OCP intervention has caused a significant reduc-
tion in the incidence of blindness from about 5% in the 
hyperendemic areas of the Upper Volta to 1% for all causes 
of blindness, while incident blindness from onchocerciasis 
appears to be no longer a problem.19 However, even in the 
treated areas of the OCP, there remain stubborn pockets of 
transmission requiring further vigilance.20
The OCP intervention is also deemed to be cost-effective. It 
is estimated that the total number of years of healthy life added 
by preventing blindness over the 20-year life of the project is 
1,098,095.21 The overall cost of the project in 2011 would be 
about US$100 million. Vector control is now applicable in 
selected areas, and is no longer regarded as the primary means 
of control of onchocerciasis. However, it should be noted that, 
in 1989, ivermectin distribution was also introduced into the 
OCP areas.18
Figure 4 Typical optic atrophy and chorioretinal and pigment epithelial disease in a 
subject infested with Onchocerca volvulus.
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Figure 5 The chemical structure of ivermectin.
to direct death of microfilariae, cross-reacting antigens may 
play a role in anterior segment lesions.12
The pathogenesis of retinochoroidal changes in onchocer-
ciasis is still controversial. Researchers have investigated 
whether or not this is due to autoimmune reactions involving 
cross-reacting antigens between O. volvulus and interpho-
toreceptor retinoid-binding proteins and immune complex 
deposition pigment epitheliopathy, but there is no consensus 
on this.12–14
The management of ocular onchocerciasis needs to be 
evaluated from the level of vector management, management 
at the community level, and management at the individual 
level, including medical and surgical management.
Vector control
Various species of the anthropophilic blood-sucking black-
fly are involved in the transmission of onchocerciasis. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Historical management  
of onchocerciasis
The treatment of onchocerciasis before 1990 was with a 
combination of diethyl carbamazine (DEC, also known as 
banucide) for the microfilaria, and suramin for the adult 
worm. Suramin is a drug developed by Oskar Dressel and 
Richard Kothe of Bayer, Germany, in 1916, and is still sold 
by Bayer under the brand name Germanin®. Suramin is a 
synthetic drug also used in the treatment of sleeping sickness 
(African trypanosomiasis) and more recently in the manage-
ment of prostatic cancer.22 For onchocerciasis, suramin is 
administered by a single weekly intravenous injection for 
six weeks. The dose per injection is 1 g. The most frequent 
adverse reactions are nausea and vomiting. About 90% of 
patients develop an urticarial rash (like a nettle or poison 
  ivy-type rash) that disappears in a few days without need-
ing to stop treatment. There is a greater than 50% chance of 
damage to the adrenal cortex, but only a small proportion of 
patients will require lifelong corticosteroid replacement. It is 
common for patients to get a tingling or crawling sensation 
of the skin with suramin. Suramin will cause clouding of the 
urine which is harmless, and patients should be warned of 
this to avoid alarm. Kidney damage and exfoliative dermatitis 
occur less commonly.23,24 Suramin is also associated with 
hepatic and bone marrow toxicity, the Stephens Johnson 
syndrome (often unreported in the author’s experience), 
and death.25,26 Of note, some reports link suramin with the 
development of optic atrophy.27
On the other hand, DEC is associated with the Mazzotti 
reaction. First described in 1948,28 the Mazzotti reaction is 
a symptom complex which can be life-threatening, and is 
characterized by fever, urticaria, swollen and tender lymph 
nodes, tachycardia, hypotension, arthralgias, edema, and 
abdominal pain that occurs within seven days of treatment for 
microfilariasis. The phenomenon is so common when DEC 
is used for the treatment of onchocerciasis that a specific 
skin patch test was developed to confirm the diagnosis. The 
drug patch is placed on the skin, and if the patient is infected 
with the microfilariae of O. volvulus, localized pruritus and 
urticaria are seen at the application site.
The prevailing hypothesis to explain the Mazzotti reaction 
is the abrupt release of parasite-specific antigens during cell 
death that induces a proinflammatory response associated with 
eosinophil migration to and degranulation in the skin. Death 
from the Mazzotti reaction has been described.29 DEC is also 
anecdotally associated with optic atrophy, possibly resulting 
from a transient optic neuritis.30,31 Using fluorescent angio-
graphic techniques, this transient neuritis was demonstrated by 
Bird et al to occur within 10–14 days of ingestion of DEC.32 
These problems made DEC unsuitable for use as a mass che-
motherapeutic agent in the management of onchocerciasis.
Nodulectomy
Mass nodulectomies were also carried out, particularly 
in the Americas. This made sense because the variant of 
onchocerciasis in the Americas was often associated with a 
preponderance of head nodules, which theoretically made it 
more likely that ocular lesions would eventuate. However, 
the effectiveness of this strategy in the long term is question-
able, given that a study in Ecuador showed a reappearance 
of nodules in hyperendemic areas.33
Chemotherapy after 1990
The serendipitous discovery of the microfilaricidal potential 
of ivermectin radically changed the prospect of onchocer-
ciasis control by chemotherapy. Ivermectin is isolated from 
the soil-dwelling mold, Streptomyces avermectilis. This 
mold was discovered by Omura et al near a golf course 
in Ito, Japan, and sent to the Merck, Sharp, and Dohme 
  laboratories in 1974.34 In 1981, ivermectin was marketed as   
a broad-spectrum anthelmintic drug in veterinary medicine, 
particularly for the dog heart worm Dirofilaria immitis. In 
1982, researchers at Merck, Sharp, and Dohme reported 
activity against O. volvulus.35 The immediate concern then 
was whether or not ivermectin caused optic neuritis and sec-
ondary optic atrophy, as did DEC. A randomized controlled 
trial carried out in Kaduna State compared ivermectin with 
placebo and found that there was a significant difference in 
the incidence of optic neuritis between the two groups.36 The 
incidence ratio of optic neuritis (ivermectin vs placebo) was 
0.90 (95% confidence interval [CI]: 0.54–1.51) for subjects 
with microfilarial loads of 0–10 microfilariae per mg of 
skin and 0.52 (CI: 0.29–0.93) for subjects with more than 
10 microfilariae per mg of skin. This suggested that ivermec-
tin reduced the incidence of optic neuritis in subjects with 
loads above 10 microfilariae per mg, but had little effect in 
those with lower loads. The implication was that sustained 
annual delivery of ivermectin could prevent a substantial 
proportion of onchocercal blindness.33 In the same trial it was 
established that ivermectin did not precipitate optic neuritis 
within 2 weeks of ingestion, as did DEC.37 This trial and 
others38,39 established the safety and efficacy of ivermectin.
Pharmacology of ivermectin
Ivermectin is a macrocyclic lactone and a synthetic derivative 
of a group of drugs called the avermectins (see Figure 5).40 Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Streptomyces avermitilis produces avermectin, a series of 
eight related pentacyclic lactones that contain a disaccharide 
of oleandrose, a methylated deoxysugar.41,42 Avermectin and 
the related compounds, milbemycin and nemadectin, are 
potent anthelmintic compounds, which are used commer-
cially in animal health care and agriculture. The semisynthetic 
derivatives, avermectin C22, C23 dihydroavermectin B1, 
and ivermectin, are widely used for the treatment of diseases 
caused by nematodes and arthropods in the veterinary and 
agricultural fields, respectively. This class of drugs was   
introduced in the early 1980s and is active against a wide vari-
ety of helminths in several domestic animals, including cattle, 
sheep, horses, dogs, and pigs.43–45 In particular, it was noted 
to be active against the microfilariae of the dog heart worm, 
D. imitis, but not against the adult worm.46,47 These drugs 
act as agonists of gamma aminobutyric acid, which is the 
neurotransmitter utilized by most susceptible helminths.48–51 
By keeping the postsynaptic chloride ion channels open when 
they should be closed, postsynaptic junctional transmissions 
are essentially blocked, leading to paralysis of the helminths.52 
The host mammals, although utilizing gamma aminobutyric 
acid as a central nervous system transmitter, are usually not 
adversely affected because the large lactone molecule does 
not cross the blood–brain barrier with any facility.53
Therefore, the obvious limitation of ivermectin is that 
it is only active against the microfilariae, and at best, has 
limited effect against the adult worm, mainly in reducing the 
fertility of the adult female, particularly in high doses.54 For 
these reasons, the primary focus is now on the development 
of a safe and effective macrofilaricidal drug capable of being 
used in mass distribution programs.
Community-directed treatment 
with ivermectin
Because ocular damage is mostly attributable to the micro-
filaria, it became necessary to find chemotherapeutic agents 
active against both the microfilaria and the adult worm (either 
singly or in combination). This is because the adult worms, 
often found coiled up in subcutaneous nodules, sometimes 
adjacent to deep muscular tendons, have a life span of about 
10–15 years and continue to produce microfilaria.
With confirmation of the efficacy and safety of ivermectin 
as a microfilaricide, it became possible to plan a control pro-
gram with ivermectin, particularly in the non-OCP countries, 
which include Nigeria and the onchocerciasis-endemic coun-
tries in central and east Africa, as well as countries in Central 
and South America. APOC was set up in 1995 to eliminate 
onchocerciasis as a disease of public health importance in 
Africa, while the equivalent program for the Americas was 
the Onchocerciasis Elimination Program for the Americas 
which commenced earlier in 1992. Merck has promised to 
make ivermectin available for distribution free of charge for 
as long as needed.55 The dosage schedule was simplified to 
utilize height rather than weight, because scales are not always 
available.56 In 1998, Merck expanded its commitment to 
include elimination of lymphatic filariasis in African   countries 
and in Yemen where lymphatic filariasis coexists with river 
blindness. The program currently reaches more than 110 mil-
lion people each year and continues to grow annually. Since 
inception of the program, Merck has donated two billion 
mectizan tablets at an estimated value of $3 billion. Com-
munity-based treatment programs for river blindness exist   
in more than 117,000 communities in 27 countries in Africa, 
five countries in Latin America, and Yemen.
At the core of the APOC and Onchocerciasis Elimina-
tion Program for the Americas strategy to eliminate the 
disease is community-directed treatment with ivermectin, 
which relies on active community participation to distribute 
ivermectin to people who need it. This successful strategy 
is now being extended to include delivery of other health 
interventions, such as insecticide-treated nets for malaria. 
A project involving this method can include up to several 
hundred communities. These communities can span a state, 
province, or an entire country. Communities eligible for 
inclusion are identified using rapid epidemiological mapping 
of onchocerciasis, rapid epidemiological assessment, and 
geographical information systems techniques.57
The project approach allows for a phased introduction of 
community-directed treatment with ivermectin in a country. 
Each project is supported by the country’s ministry of health 
and a nongovernmental development organization in most 
countries. As of the end of 2007, APOC was running 108 
projects in 16 countries, and over 127,000 communities 
were involved.58 In Nigeria, for instance, there are projects 
in 27 states, including the Federal Capital Territory.
With the APOC mandate due to end in 2015, every effort 
is being made to ensure that the substantial investments and 
progress made towards eliminating onchocerciasis in Africa 
are sustained for the future. By 2015, APOC aims to transfer 
full responsibility for onchocerciasis control to local   ministries 
of health, to encourage the ministries to provide ongoing finan-
cial support, and to encourage nongovernmental development 
organizations to continue to play their critical role. The goal 
is to establish country-led systems capable of   eliminating 
onchocerciasis as a public health problem in all endemic 
countries in Africa. The Yaoundé Declaration was signed by Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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African ministers of health in 2006. It expresses a renewed 
commitment to work towards the elimination of onchocerciasis 
in all countries where it is a public health problem.
There are challenges to the execution of the community-
directed treatment with ivermectin projects as stated by 
Amazigo et al.59 These include timely collection of drugs, 
integration of community-directed treatment with ivermectin 
into existing primary health care services, strengthening of 
local health infrastructure, achievement of optimal treat-
ment coverage, establishment and upscaling of community 
self-monitoring, designing and implementing operations 
research locally, ensuring the adequacy of community-
directed distributors, and increasing the involvement of local 
nongovernmental organizations. Others are the achievement 
of financial sustainability and cost-recovery systems and 
effective advocacy. Coverage so far has varied from place to 
place. The following are not eligible to receive ivermectin: 
children five years or younger, pregnant women, and the 
obviously sick.60 However, coverage is deemed satisfactory 
where $90% of the annual treatment objective is met, as is 
the case of communities in Uganda,61 the annual treatment 
objective being the number of persons at risk of onchocercia-
sis in any given area of community-directed treatment with 
ivermectin who are estimated to require treatment.
Adverse drug events have been reported with ivermectin, 
but these have been generally mild, except in areas where 
there are overlaps with Loa loa.62 In Sierra Leone, 28 (32%) 
of 87 patients had adverse reactions that required treatment 
with acetylsalicylic acid and antihistamines, but none of the 
observed adverse reactions were considered life-threatening. 
The incidence of the Mazzotti reaction during treatment of 
onchocerciasis with ivermectin runs at approximately 10%, 
which is much lower than that seen with DEC. Even so, 
nearly one-quarter of patients treated with ivermectin develop 
isolated fever or itching without the remaining constellation 
of symptoms. Because of its better safety profile, ivermectin 
has supplanted DEC as the drug of choice for the treatment of 
onchocerciasis.63 A significant relationship was found between 
the frequency and severity of side effects and the degree of 
parasite infestation.64 In Nigeria, a later study indicated that 
most of the reactions were experienced in the first round of 
dosing, and the frequency reduced with subsequent rounds. The 
most serious side effect noted in that study was joint pains.65
Side effects with coexistent loiasis
Several cases of encephalopathy have been reported after 
ivermectin in people heavily infected with the microfilariae 
of L. loa (loiasis).66 The relative risk of developing marked 
or serious reactions was significantly higher when the L. loa 
load exceeded 8000 microfilariae per mL. The risk is very high 
(odds ratio .1000) for loads above 50,000 microfilariae per 
mL. Epidemiological surveys aimed at assessing the intensity 
of infection with L. loa microfilariae, now called RAPLOA 
(Rapid Assessment Procedures for Loiasis) are now being 
carried out by WHO. Pictures of the L. loa worm are shown 
to communities for recognition. Those communities with a 
high rate of recognition are presumed to have high endemicity 
of Loiasis. This assessment should be carried out before iver-
mectin is distributed for onchocerciasis control in areas where 
loiasis is endemic. The most affected areas at the moment 
are the Cameroons and adjacent central African countries. In 
communities at risk, monitoring procedures should be estab-
lished and adhered to during community-based ivermectin 
treatment, so that people developing serious reactions may 
receive appropriate treatment.66
Interruption of transmission
Ivermectin is mainly a microfilaricide but, in addition, has 
the effect of suppressing production of microfilaria by adult 
worms. However, this means that treatment would need to be 
continued for at least 15 years, which is the projected length 
of life of the adult. It has been debated as to whether or not 
this can lead to interruption of transmission. One study sug-
gests that interruption is not likely to happen.67
In all of the river basins studied, treatment with   ivermectin 
sharply reduced the prevalence and intensity of   infection. 
However, significant transmission is still ongoing in some 
basins after 10–12 years of ivermectin treatment. In other 
basins, transmission may have been interrupted, but this needs 
to be confirmed by indepth evaluation. In one mesoendemic 
basin, where 20 rounds of 4-monthly treatment reduced 
prevalence of infection to levels as low as 2%–3%, there was 
significant recrudescence of infection within a few years after 
interruption of treatment.68 These studies were carried out 
in West Africa. However, there are some important differ-
ences with the situation in the Americas where, by and large, 
the blackfly vector may not be as efficient, and population 
migrations are not a critical factor as they are in Africa.69 
Using biannual ivermectin dosing with a high coverage, it 
has been possible to interrupt transmission in the Oaxaca 
focus in southern Mexico.70 In Latin America, transmission 
has been interrupted in half of the original endemic foci. In 
addition, Columbia appears to be the first country to report a 
nationwide elimination of onchocerciasis in the Americas.69,70 
However, within Africa, there are isolated reports of elimina-
tion using ivermectin, particularly in Senegal and Mali.71Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Resistance to ivermectin
Some disturbing instances of resistance have been reported 
in Africa.72 Workers in Ghana found that in some commu-
nities adult female worms were nonresponsive or resistant 
to the antireproductive effects of multiple treatments with 
ivermectin. These workers confirmed resistance by examin-
ing microfilaria repopulation levels one year after treatment, 
worm burdens per nodule, the age structure of adult female 
worms recovered from nodules, and the reproductive status 
of adult female worms 90 days after ivermectin treatment. 
They concluded that, in some communities, there was a loss 
of the effect of ivermectin on the suppression of parasite 
reproduction using the parameters stated.
There is also anecdotal evidence that some community-
directed treatment with ivermectin programs in the North 
Eastern area of Nigeria have already adopted higher 
  frequency treatment due to poor response of skin lesions to 
annual therapy. Should resistance become more common-
place, the whole platform of the mass drug administration 
program might be in jeopardy, especially in Africa.
Need for newer microfilaricides  
and macrofilaricides
The challenges of maintaining distribution over a prolonged 
period, especially with the proposed cessation of funding 
of APOC and Onchocerciasis Elimination Program for the 
Americas programs in 2015, the recrudescence of transmis-
sion even in the face of continued community-directed treat-
ment with ivermectin, and the possibility of development of 
resistance to ivermectin in the future (if not already) all make 
it urgent and necessary to develop newer drugs. Also, where 
there are overlapping foci involving lymphatic filariasis 
and L. loa, drug combinations may be necessary to prevent 
development of serious sequelae, such as encephalopathy. 
There are several candidate drugs on the horizon, some of 
which are undergoing trials.
Moxidectin
Moxidectin (milbemycin B) is a semisynthetic deriva-
tive of nemadectin which is produced by fermentation of 
  Streptomyces cyanogriseus. This Streptomyces was discov-
ered in a soil sample from Australia in the late 1980s col-
lected by an agronomist working for American Cyanamid 
Company. Moxidectin treats and controls some of the most 
common internal and external parasites by selectively bind-
ing to the glutamate-gated chloride ion channels in parasites. 
These channels are vital to the function of invertebrate nerve 
and muscle cells; when moxidectin binds to the channels, 
it   disrupts neurotransmission, resulting in paralysis and death 
of the parasite. Preclinical data in animal models suggest that 
moxidectin may either sterilize or kill the adult worm.73,74 
Ivermectin does not do that, even though repeated treatments 
reduce the reproductive capacity of the adult worms. Drug 
trials in humans have therefore begun with moxidectin. A trial 
is being conducted by the Special Programme for Research 
and Training in Tropical Diseases, an independent global pro-
gram sponsored by the United Nations Children’s Fund, the 
World Bank, and the WHO. The trial will be enrolling 15, 000 
people for the study at four sites in Ghana, Liberia, and the 
Democratic Republic of Congo. The programme will involve 
African investigators and institutions.75 Subjects participating 
in the study will be randomly assigned (in a 2 to 1 ratio) to 
receive one orally administered dose of either moxidectin 
or ivermectin. The aim is to have a treatment that can be 
administered once or twice a year to interrupt transmission 
of the disease. At the moment, ivermectin needs to be given 
once or twice a year for 11–15 years to ensure control of the 
disease. Researchers believe moxidectin has the potential 
to control the disease after six cycles of treatment.76 Animal 
studies of moxidectin show that side effects vary by animal 
species, and may be affected by the product formulation, 
application method, and dosage.
Flubendazole
Flubendazole is another candidate macrofilaricide for 
onchocerciasis field programs.77 It is a very efficacious 
macrofilaricide in a variety of experimental animals, with 
perhaps its most dramatic and relevant action being an ability 
to eliminate adult D. immitis completely from dogs after a 
single injection. It was developed by Janssen in the mid 1970s 
and is currently licensed in Europe for use as an anthelm-
intic for humans with intestinal nematodes. In a number of 
experimental filarial rodent models, flubendazole had shown 
essentially 100% efficacy as a macrofilaricide at reasonable 
doses and schedules. A trial in human onchocerciasis was 
carried out in Mexico in the early 1980s78 with promising 
results. Previous tests against Brugia Pahangi suggested that 
flubendazole may be active against adult tissue-dwelling 
filaria, but not against the microfilaria.79
However, wider testing in humans was restricted at that 
time by problems associated with the parenteral route of 
administration and the relatively unsophisticated carrier 
agent used, about 30 years ago. In addition, the introduc-
tion of ivermectin lessened the urgency to replace DEC for 
onchocerciasis control with a new macrofilaricide. In its cur-
rently available oral formulation, flubendazole is licensed in Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Europe for intestine-dwelling parasites. It is effective in this 
way because it does not need to be taken up into tissue. For it 
to be effective in an oral formulation against tissue-dwelling 
parasites such as O. volvulus, new excipients will need to be 
developed. One such promising excipient is hydroxypropyl-
β-cyclodextrin.80 Recent tests suggest that the cyclodextrin 
formulation could be effective against tissue-dwelling 
  helminth parasites.81 The Bill and Melinda Gates Founda-
tion is supporting a group of scientists enigmatically called 
“DOLF” (Death of Onchocerciasis and Lymphatic Filariasis) 
based at Washington University (St Louis, MO). Among 
other activities, this group is carrying out clinical trials on 
candidate macrofilaricides, including a new flubendazole 
formulation, against onchocerciasis.82
Albendazole
Albendazole is one of the benzimidazole group of drugs that 
is somewhat useful in onchocerciasis control. Albendazole 
was first discovered at the SmithKline Animal Health Labora-
tories in 1972. It is only available as an oral   formulation. It is 
a broad-spectrum anthelmintic effective against roundworms, 
tapeworms, and flukes of domestic animals and humans. 
Albendazole (donated by GlaxoSmithKline) is being used to 
treat lymphatic filariasis as part of efforts to stop transmis-
sion of the disease in conjunction with ivermectin in sub-
Saharan Africa, and with DEC elsewhere in the world. It is 
not strictly speaking a microfilaricidal for O. volvulus, but 
does have significant chemosterilant properties. It is believed 
to potentiate the effect of the microfilaricidal properties of 
ivemectin, and when used in this combination, can reduce 
microfilariasis by up to 99% for a year.83,84
The WHO Global Program to Eliminate Lymphatic 
Filariasis works actively to combat lymphatic filariasis by 
developing alternative and effective mass drug administra-
tion regimens and strategies. It aims to eliminate lymphatic 
filariasis globally by 2020. A higher dose of albendazole or 
biannual treatment is being trialed. As stated, where there are 
overlapping areas of onchocerciasis endemicity, albendazole 
is used alongside ivermectin, and the potentiating effect 
becomes an advantage.85
Antibiotics targeting wolbachia
The symbiotic relationship between Wolbachia and the 
adult worms has been well elucidated.86 Most filarial 
species that infect people are symbiotic with Wolbachia 
bacteria, which are essential for the growth, development, 
and survival of their nematode hosts. This is probably 
because the worms are dependent on the bacteria for 
heme   synthesis.87 These endosymbionts contribute to the 
pathogenesis of inflammatory disease and are a target for 
doxycycline   therapy, which has macrofilaricidal   activity, 
improves pathologic outcomes, and is as effective as 
monotherapy.88–90
Doxycycline 100 mg/day orally for 6 weeks targets 
endosymbiotic bacteria and results in long-term sterility of 
the adult female worms and in a corresponding absence of 
microfilariae. In Ghana, when ivermectin was given after 
doxycycline, it resulted in a strong and sustained (18-month) 
reduction of microfilariae loads to levels of less than 
0.3 microfilariae per mg. This may be a useful adjunctive 
therapy to ivermectin.89
Coterminal foci of filarial infection
As already noted, it is not uncommon in the African setting 
and elsewhere for more than one type of filarial disease to 
exist in the same focus. In such situations, mass chemo-
therapy needs to be planned taking this into consideration. 
There are nine known filarial nematodes which use humans as 
their definitive host.91–93 These are divided into three groups 
according to the niche within the body that they occupy, ie, 
serous cavity filariasis, lymphatic filariasis, and subcutaneous 
filariasis.   Lymphatic filariasis is caused by the Brugia malayi, 
  Wuchereria   bancrofti, and Brugia timori worms. As the 
name suggests, these worms tend to occupy the lymphatic 
system, including the vessels and nodes, and are associated 
with development of elephantiasis. Lymphatic filariasis is 
transmitted by different types of mosquitoes, such as the 
Culex mosquito, Anopheles mainly in rural areas, and Aedes, 
mainly in endemic islands in the Pacific. Subcutaneous filari-
asis is caused by L. loa (the African eyeworm), Mansonella 
streptocerca, O. volvulus, and Dracunculus medinensis 
(the guinea worm). These worms occupy the subcutaneous 
layer of the skin, in the fat layer. Serous cavity filariasis is 
caused by the worms Mansonella perstans and Mansonella 
ozzardi, which occupy the serous cavity of the abdomen. In 
all cases, the transmitting vectors are either blood-sucking 
insects (flies or mosquitoes), or copepod crustaceans in the 
case of Dracunculus medinensis.
The recommended regimen for treatment through mass 
drug administration is a single dose of the two medicines 
given together, ie, albendazole 400 mg plus either   ivermectin 
150–200 µg/kg in areas where onchocerciasis (river blindness) 
is also endemic or DEC 6 mg/kg in areas where onchocerciasis 
is not endemic. These medicines clear microfilariae from the 
bloodstream and kill most of the adult worms. However, at 
present, as noted earlier, ivermectin treatment is best avoided Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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in areas where L. loa is also endemic to avoid the serious 
side effects.
Impact of therapy on skin disease
Workers suggest that the prevalence and severity of reactive 
skin lesions decrease with the use of ivermectin;94 in particu-
lar itching, which is one of the most disturbing aspects of 
morbidity, is reduced in frequency and intensity. The effect 
of long-term treatment on more chronic lesions was recently 
investigated by Ozoh et al.95 Significant reductions were 
found in all grades of skin disease after about five years of 
ivermectin therapy.
Nuisance value of the blackfly
It must be borne in mind that mass drug administration does 
not get rid of the blackfly. Outside the OCP in West Africa, 
vector control has been carried out only in selected areas. The 
nuisance value of the blackfly must not be underestimated. 
For instance, in the Democratic Republic of the Congo, 
the nuisance of S. damnosum represents a real problem on 
the Inga Dam and the two neighboring health zones (Inga 
and   Seke-Banza), particularly during the high water period 
of the river between October and December. A total of 
163,823 persons live in the area. Since cessation of vector 
control activities three decades ago, the daily biting rate has 
increased from 10 to 13,000 bites/person/day.96 This had seri-
ous negative health, social, and economic effects on workers 
and their families, in particular on school children, impairing 
their performance at school. APOC and WHO subsequently 
raised money for larviciding activity to control this menace. 
Other APOC zones have not been so lucky. There is still a 
need for larviciding where the biting rate is higher than an 
acceptable threshold.96
Impact of longitudinal  
treatment with ivermectin
This is summarized in Table 1. The impact of mass drug 
administration has been felt in the endemic areas and has, 
from estimates in 2006, prevented 500,000 cases of blind-
ness, treated 20 million cases of severe itching, and averted 
500,000 disability-adjusted life years per annum.97 The OCP, 
on the other hand, is estimated to have prevented 600,000 
cases of blindness and allowed the reclamation of 25 million 
hectares of arable land.97 When specific ocular parameters 
are assessed, some workers suggest that there is a reversal of 
early ocular lesions, particularly snowflake opacities.98 The 
incidence of optic neuritis is also significantly reduced.37,99 
However, there is controversy over the impact on visual 
Table 1 impact of longitudinal treatment with mectizan on certain 
parameters
Source Finding
APOC 1996–200597 20 million cases of severe itching prevented
APOC 1996–200597 500,000 cases of blindness prevented
APOC 1996–200597 500,000 DALYs per year averted at US$7  
per DALY
APOC 1996–200597 economic rate of return of 17%
Abiose et al36 Prevention of new cases of optic neuritis  
and prevention of optic nerve disease
Abiose98 Regression of early ocular lesions, including 
sclerosing keratitis
Cousens et al99 A reduction in incidence of visual field loss
ejere et al  
(cochrane review)100
No statistically significant difference was 
observed in any trial (reporting visual acuity 
outcome) between ivermectin and placebo 
groups for visual acuity loss; questions about  
the effectiveness of ivermectin in preventing 
visual acuity loss have not been answered by 
best available evidence
Kennedy et al101 No change in the prevalence of ocular 
signs such as punctate keratitis, sclerosing 
keratitis, iridocyclitis, optic nerve atrophy, 
cataract, glaucoma, chorioretinitis
Abbreviations:  APOC,  African  Program  for  Onchocerciasis  Control;  DALY, 
disability-adjusted life years.
acuity, with a Cochrane review suggesting that there is no 
effect on this parameter.100 This seems consistent with the 
findings of Kennedy et al who followed mectizan users for 
five years and found no changes in the prevalence of main 
ocular lesions in this cohort.101 Interestingly, in the same 
paper, they reported a reduction in the prevalence of blind-
ness, but it was not clear how this came about. There are 
perhaps obscure epidemiologic reasons for this. Patients with 
established ocular lesions may not benefit from treatment, and 
their visual acuity will likely remain unchanged. However, a 
reduced incidence of ocular involvement is expected, which 
over time will impact the overall prevalence of ocular lesions 
and indirectly impact the prevalence of blindness and visual 
impairment from onchocerciasis.
Conclusion
Ivermectin monotherapy through mass drug administration 
has had some positive impact on skin and ocular morbidity 
and incident blindness, but these gains may be fragile because 
of the possibility of drug resistance, and the need for sus-
tained treatment for up to 15 years. The outcome of ongoing 
randomized controlled studies of candidate microfilaricides 
and safe macrofilaricides are eagerly awaited. In addition, 
areas where vector control can be of particular use need to 
be identified. Overall, the prospects of control are high, but Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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comprehensive global eradication may not be achievable 
with current tools.
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